Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Gantz

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Diabetes Research and Clinical Practice|October 29, 2017
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetesPhilip Home, R Ravi Shankar, Ira Gantz, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2025
Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASHAnnaswamy Raji, Ira Gantz, Michael Crutchlow, et al.
Diabetes, Obesity & Metabolism|July 24, 2020
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studiesRichard Pratley, Samuel Dagogo-Jack, Bernard Charbonnel, et al.
Patient Preference and Adherence|October 3, 2013
Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetesA Brett Hauber, Steven Han, Jui-Chen Yang, et al.
Obesity (Silver Spring, Md.)|April 12, 2007
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight lossNgozi Erondu, Thomas Wadden, Ira Gantz, et al.
Diabetes, Obesity & Metabolism|December 19, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trialFrancesco Cosentino, Samuel Dagogo-Jack, Robert Frederich, et al.
Peptides|July 16, 2003
Inverse agonist activity of agouti and agouti-related proteinBiao-Xin Chai, Richard R Neubig, Glenn L Millhauser, et al.
Kidney Diseases (Basel, Switzerland)|March 3, 2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV TrialDavid Z I Cherney, Robert Frederich, Richard E Pratley, et al.
BMJ Open Diabetes Research & Care|October 8, 2021
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trialSamuel Dagogo-Jack, Richard E Pratley, David Z I Cherney, et al.
Diabetologia|April 3, 2020
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trialsDavid Z I Cherney, Hiddo J L Heerspink, Robert Frederich, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Diabetes Research and Clinical Practice|October 29, 2017
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetesPhilip Home, R Ravi Shankar, Ira Gantz, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2025
Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASHAnnaswamy Raji, Ira Gantz, Michael Crutchlow, et al.
Diabetes, Obesity & Metabolism|July 24, 2020
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studiesRichard Pratley, Samuel Dagogo-Jack, Bernard Charbonnel, et al.
Patient Preference and Adherence|October 3, 2013
Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetesA Brett Hauber, Steven Han, Jui-Chen Yang, et al.
Obesity (Silver Spring, Md.)|April 12, 2007
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight lossNgozi Erondu, Thomas Wadden, Ira Gantz, et al.
Diabetes, Obesity & Metabolism|December 19, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trialFrancesco Cosentino, Samuel Dagogo-Jack, Robert Frederich, et al.
Peptides|July 16, 2003
Inverse agonist activity of agouti and agouti-related proteinBiao-Xin Chai, Richard R Neubig, Glenn L Millhauser, et al.
Kidney Diseases (Basel, Switzerland)|March 3, 2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV TrialDavid Z I Cherney, Robert Frederich, Richard E Pratley, et al.
BMJ Open Diabetes Research & Care|October 8, 2021
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trialSamuel Dagogo-Jack, Richard E Pratley, David Z I Cherney, et al.
Diabetologia|April 3, 2020
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trialsDavid Z I Cherney, Hiddo J L Heerspink, Robert Frederich, et al.
Pageof 7